Dec 21 (Reuters) - Novavax said on Tuesday the World Health Organization's (WHO) panel of experts had recommended a third dose of its vaccine, NVX-CoV2373, for immunocompromised persons.The WHO's Strategic Advisory Group of Experts on Immunization, known as SAGE, issued a series of recommendations, including the use of the vaccine in persons with comorbidities, breastfeeding women, and those living with HIV.After reviewing Novavax data the independent experts said the vaccine could be used in pregnant women if the benefits of vaccination to the pregnant woman outweigh the potential risks.On Friday, the WHO issued an emergency use listing to Novavax's vaccine made by the Serum Institute of India, the world's biggest vaccine maker, paving the way for its use in low- and middle-income countri

Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck."We will be filing within the next few days in the U.S.," Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat

Novavax (NVAX) is finally ready to submit its application for emergency use authorization (EUA) in the U.S., and could do so as early as this week, according to CEO Stanley Erck."We will be filing within the next few days in the U.S.," Erck told Yahoo Finance Live on Tuesday.The company has made significant progress on its path to its first commercial product, the two-dose COVID-19 vaccine, marking three major milestones in the past week.Novavax has now received four emergency use approvals, including a listing from the World Health Organization, making it the ninth vaccine authorized by the agency, as well as conditional marketing in the European Union. In addition, the company announced administering its first dose in Indonesia Tuesday, where it recently received emergency use authorizat